Skip to main content
SpringerLink
Log in

Epidemiology, Screening, and Clinical Staging

  • Chapter
  • First Online:
Renal Cancer

Abstract

In this chapter, we discuss the epidemiology of renal cell carcinoma including its risk factors and current demographic composition. Additionally, changes over time in particular with the increasing use of CT scanning are discussed. Evidence for screening protocols for specific populations at risk, such as those with genetic syndromes, is analyzed. Finally, the literature that led to the development and continued refinement of the TNM and other staging systems is reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12):2893–917.

    Article  PubMed  CAS  Google Scholar 

  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.

    Article  PubMed  Google Scholar 

  4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.

    Article  PubMed  Google Scholar 

  5. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003;8(6): 541–52.

    Article  PubMed  Google Scholar 

  6. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. NEJM. 1996;335(12):865–75.

    Article  PubMed  CAS  Google Scholar 

  7. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, et al. Classification of renal cell carcinoma: workgroup no. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):987–9.

    Article  PubMed  CAS  Google Scholar 

  8. Patard JJ. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2004;23(12):2763–71.

    Article  Google Scholar 

  9. Beck SDW. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2003;11(1): 71–7.

    Article  Google Scholar 

  10. Dall’Oglio MF, Antunes AA, Pompeo AC, Mosconi A, Leite KR, Srougi M. Prognostic relevance of the histological subtype of renal cell carcinoma. Int Braz J Urol. 2008;34(1):3–8.

    Article  PubMed  Google Scholar 

  11. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2011.

    Google Scholar 

  12. Mindrup SR, Pierre JS, Dahmoush L, Konety BR. The prevalence of renal cell carcinoma diagnosed at autopsy. BJU Int. 2005;95(1):31–3.

    Article  PubMed  Google Scholar 

  13. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration. Cancer. 2008;113(1):78–83.

    Article  PubMed  Google Scholar 

  14. Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281(17):1628–31.

    Article  PubMed  CAS  Google Scholar 

  15. Mariotto AB, Robin Yabroff K, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. JNCI J Natl Cancer Inst. 2011;103(2):117–28.

    Article  Google Scholar 

  16. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma – age and stage characterization and clinical implications: study of 1092 patients (1982–1997). Urology. 2000;56(1):58–62.

    Article  PubMed  CAS  Google Scholar 

  17. Verhoest G, Veillard D, Guillé F, Taille ADL, Salomon L, Abbou CC, et al. Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol. 2007;51(5): 1298–305.

    Article  PubMed  Google Scholar 

  18. Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol. 2008;54(1):133–42.

    Article  PubMed  Google Scholar 

  19. Silverberg E, Grant RN. Cancer statistics, 1970. CA Cancer J Clin. 1970;20(1):11–23.

    Article  PubMed  CAS  Google Scholar 

  20. Boring CC, Squires TS, Tong T. Cancer statistics, 1991. Bol Asoc Med P R. 1991;83(6):225–42.

    PubMed  CAS  Google Scholar 

  21. Woldrich JM, Mallin K, Ritchey J, Carroll PR, Kane CJ. Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993–2004. J Urol. 2008;179(5):1709–13. Discussion 13.

    Article  PubMed  Google Scholar 

  22. Vaishampayan UN, Do H, Hussain M, Schwartz K. Racial disparity in incidence patterns and outcome of kidney cancer. Urology. 2003;62(6):1012–7.

    Article  PubMed  CAS  Google Scholar 

  23. Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol. 2008;179(5):1704–8.

    Article  PubMed  Google Scholar 

  24. Sankin A, Cohen J, Wang H, Macchia RJ, Karanikolas N. Rate of renal cell carcinoma subtypes in different races. Int Braz J Urol. 2011;37(1):29–32. Discussion 3–4.

    Article  PubMed  Google Scholar 

  25. Berndt SI, Carter HB, Schoenberg MP, Newschaffer CJ. Disparities in treatment and outcome for renal cell cancer among older black and white patients. J Clin Oncol. 2007;25(24):3589–95.

    Article  PubMed  Google Scholar 

  26. Saigal CS, Deibert CM, Lai J, Schonlau M. Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma. Urol Oncol Semin Orig Invest. 2010;28(3):308–13.

    Article  Google Scholar 

  27. Broecker B. Non-Wilms’ renal tumors in children. Urol Clin North Am. 2000;27(3):463–9. ix.

    Article  PubMed  CAS  Google Scholar 

  28. Kubo M, Iwashita K, Oyachi N, Oyama T, Yamamoto T. Two different types of infantile renal cell carcinomas associated with tuberous sclerosis. J Pediatr Surg. 2011;46(10):e37–41.

    Article  PubMed  Google Scholar 

  29. Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, et al. Translocation renal cell ­carcinoma. Cancer. 2008;112(7):1607–16.

    Article  PubMed  Google Scholar 

  30. Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med. 2005;25(2):363–78.

    Article  PubMed  Google Scholar 

  31. Yamaguchi T, Fukuda T, Uetani M, Hayashi K, Kurosaki N, Maeda H, et al. Renal cell carcinoma in a patient with Beckwith-Wiedemann syndrome. Pediatr Radiol. 1996;26(5):312–4.

    Article  PubMed  CAS  Google Scholar 

  32. Indolfi P. Renal cell carcinoma in children: a clinicopathologic study. J Clin Oncol. 2003;21(3):530–5.

    Article  PubMed  Google Scholar 

  33. Sanchez-Ortiz RF, Rosser CJ, Madsen LT, Swanson DA, Wood CG. Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol. 2004;171(6 Pt 1):2160–5.

    Article  PubMed  Google Scholar 

  34. La Vecchia C, Negri E, D’Avanzo B, Franceschi S. Smoking and renal cell carcinoma. Cancer Res. 1990;50(17):5231–3.

    PubMed  Google Scholar 

  35. Yuan JM, Castelao JE, Gago-Dominguez M, Yu MC, Ross RK. Tobacco use in relation to renal cell carcinoma. Cancer Epidemiol Biomark Prev. 1998;7(5): 429–33.

    CAS  Google Scholar 

  36. McLaughlin JK, Hrubec Z, Heineman EF, Blot WJ, Fraumeni Jr JF. Renal cancer and cigarette smoking in a 26-year followup of U.S. veterans. Public Health Rep. 1990;105(5):535–7.

    PubMed  CAS  Google Scholar 

  37. Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005;114(1):101–8.

    Article  PubMed  CAS  Google Scholar 

  38. McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni Jr JF. A population–based case–control study of renal cell carcinoma. J Natl Cancer Inst. 1984;72(2):275–84.

    PubMed  CAS  Google Scholar 

  39. Yuan JM, Castelao JE, Gago-Dominguez M, Ross RK, Yu MC. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br J Cancer. 1998;77(9):1508–13.

    Article  PubMed  CAS  Google Scholar 

  40. Chow WH, Gridley G, Fraumeni Jr JF, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343(18):1305–11.

    Article  PubMed  CAS  Google Scholar 

  41. Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer–a quantitative review. Br J Cancer. 2001;85(7):984–90.

    Article  PubMed  CAS  Google Scholar 

  42. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78.

    Article  PubMed  Google Scholar 

  43. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91.

    Article  PubMed  CAS  Google Scholar 

  44. Moyad MA. Obesity, interrelated mechanisms, and exposures and kidney cancer. Semin Urol Oncol. 2001;19(4):270–9.

    PubMed  CAS  Google Scholar 

  45. Lowrance WT, Thompson RH, Yee DS, Kaag M, Donat SM, Russo P. Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int. 2010;105(1):16–20.

    Article  PubMed  Google Scholar 

  46. Ogden CL. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA Journal Am Med Assoc. 2006;295(13):1549–55.

    Article  CAS  Google Scholar 

  47. Heath Jr CW, Lally CA, Calle EE, McLaughlin JK, Thun MJ. Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Am J Epidemiol. 1997;145(7):607–13.

    Article  PubMed  Google Scholar 

  48. Shapiro JA, Williams MA, Weiss NS, Stergachis A, LaCroix AZ, Barlow WE. Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am J Epidemiol. 1999;149(6):521–30.

    Article  PubMed  CAS  Google Scholar 

  49. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med. 2002;112(6):479–86.

    Article  PubMed  Google Scholar 

  50. Colt JS, Schwartz K, Graubard BI, Davis F, Ruterbusch J, DiGaetano R, et al. Hypertension and risk of renal cell carcinoma among White and Black Americans. Epidemiology. 2011;22(6):797–804.

    PubMed  Google Scholar 

  51. Grossman E. Antihypertensive therapy and the risk of malignancies. Eur Hear J. 2001;22(15):1343–52.

    Article  CAS  Google Scholar 

  52. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer. 1999;81(3): 542–8.

    Article  PubMed  CAS  Google Scholar 

  53. Cho E, Curhan G, Hankinson SE, Kantoff P, Atkins MB, Stampfer M, et al. Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med. 2011;171(16):1487–93.

    Article  PubMed  Google Scholar 

  54. Rashidkhani B, Lindblad P, Wolk A. Fruits, vegetables and risk of renal cell carcinoma: a prospective study of Swedish women. Int J Cancer. 2005; 113(3):451–5.

    Article  PubMed  CAS  Google Scholar 

  55. Lee JE, Mannisto S, Spiegelman D, Hunter DJ, Bernstein L, van den Brandt PA, et al. Intakes of fruit, vegetables, and carotenoids and renal cell cancer risk: a pooled analysis of 13 prospective studies. Cancer Epidemiol Biomark Prev. 2009;18(6):1730–9.

    Article  CAS  Google Scholar 

  56. Handa K, Kreiger N. Diet patterns and the risk of renal cell carcinoma. Public Health Nutr. 2007;5(06): 757–67.

    Google Scholar 

  57. Daniel CR, Schwartz KL, Colt JS, Dong LM, Ruterbusch JJ, Purdue MP, et al. Meat-cooking mutagens and risk of renal cell carcinoma. Br J Cancer. 2011;105(7):1096–104.

    Article  PubMed  CAS  Google Scholar 

  58. Daniel CR, Cross AJ, Graubard BI, Park Y, Ward MH, Rothman N, et al. Large prospective investigation of meat intake, related mutagens, and risk of renal cell carcinoma. Am J Clin Nutr. 2011;95(1): 155–62.

    Article  PubMed  CAS  Google Scholar 

  59. Lee JE, Hunter DJ, Spiegelman D, Adami HO, Albanes D, Bernstein L, et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. JNCI J Natl Cancer Inst. 2007;99(10): 801–10.

    Article  Google Scholar 

  60. Lee JE, Hunter DJ, Spiegelman D, Adami HO, Bernstein L, van den Brandt PA, et al. Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies. Int J Cancer. 2007;121(10):2246–53.

    Article  PubMed  CAS  Google Scholar 

  61. Bruning T, Pesch B, Wiesenhutter B, Rabstein S, Lammert M, Baumuller A, et al. Renal cell cancer risk and occupational exposure to trichloroethylene: results of a consecutive case-control study in Arnsberg, Germany. Am J Indus Med. 2003;43(3): 274–85.

    Article  Google Scholar 

  62. Vamvakas S, Bruning T, Thomasson B, Lammert M, Baumuller A, Bolt HM, et al. Renal cell cancer correlated with occupational exposure to trichloroethene. J Cancer Res Clin Oncol. 1998;124(7):374–82.

    Article  PubMed  CAS  Google Scholar 

  63. Gates TJ. Screening for cancer: evaluating the evidence. Am Fam Physician. 2001;63(3):513–22.

    PubMed  CAS  Google Scholar 

  64. Leslie JA, Prihoda T, Thompson IM. Serendipitous renal cell carcinoma in the post-CT era: continued evidence in improved outcomes. Urol Oncol. 2003; 21(1):39–44.

    Article  PubMed  Google Scholar 

  65. Parsons JK, Schoenberg MS, Carter HB. Incidental renal tumors: casting doubt on the efficacy of early intervention. Urology. 2001;57(6):1013–5.

    Article  PubMed  CAS  Google Scholar 

  66. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331–4.

    Article  PubMed  Google Scholar 

  67. Murakami S, Igarashi T, Hara S, Shimazaki J. Strategies for asymptomatic microscopic hematuria: a prospective study of 1034 patients. J Urol. 1990; 144(1):99–101.

    PubMed  CAS  Google Scholar 

  68. Warshauer DM, McCarthy SM, Street L, Bookbinder MJ, Glickman MG, Richter J, et al. Detection of renal masses: sensitivities and specificities of excretory urography/linear tomography, US, and CT. Radiology. 1988;169(2):363–5.

    PubMed  CAS  Google Scholar 

  69. Malaeb BS, Martin DJ, Littooy FN, Lotan Y, Waters WB, Flanigan RC, et al. The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elderly asymptomatic population. BJU Int. 2005;95(7):977–81.

    Article  PubMed  Google Scholar 

  70. Mihara S, Kuroda K, Yoshioka R, Koyama W. Early detection of renal cell carcinoma by ultrasonographic screening–based on the results of 13 years screening in Japan. Ultrasound Med Biol. 1999;25(7): 1033–9.

    Article  PubMed  CAS  Google Scholar 

  71. Brown EA. Renal tumours in dialysis patients: who should we screen? Nephron Clin Pract. 2004;97(1): c3–4.

    Article  PubMed  Google Scholar 

  72. Ishikawa I, Honda R, Yamada Y, Kakuma T. Renal cell carcinoma detected by screening shows better patient survival than that detected following symptoms in dialysis patients. Ther Apher Dial. 2004; 8(6):468–73.

    Article  PubMed  Google Scholar 

  73. Sarasin FP, Wong JB, Levey AS, Meyer KB. Screening for acquired cystic kidney disease: a decision analytic perspective. Kidney Int. 1995;48(1): 207–19.

    Article  PubMed  CAS  Google Scholar 

  74. Neuzillet Y, Lay F, Luccioni A, Daniel L, Berland Y, Coulange C, et al. De novo renal cell carcinoma of native kidney in renal transplant recipients. Cancer. 2005;103(2):251–7.

    Article  PubMed  Google Scholar 

  75. Moudouni SM, Lakmichi A, Tligui M, Rafii A, Tchala K, Haab F, et al. Renal cell carcinoma of native kidney in renal transplant recipients. BJU Int. 2006;98(2): 298–302.

    Article  PubMed  Google Scholar 

  76. Denton MD, Magee CC, Ovuworie C, Mauiyyedi S, Pascual M, Colvin RB, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int. 2002;61(6):2201–9.

    Article  PubMed  Google Scholar 

  77. Fenton JJ, Weiss NS. Screening computed tomography: will it result in overdiagnosis of renal carcinoma? Cancer. 2004;100(5):986–90.

    Article  PubMed  Google Scholar 

  78. Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004;64(15):5511–7.

    Article  PubMed  CAS  Google Scholar 

  79. Dubiel JP, Bielecki A, Ciba T. Effects of Sadamin and Complamin on left ventricular function. Pol Tyg Lek. 1973;28(12):430–3.

    PubMed  CAS  Google Scholar 

  80. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059–67.

    Article  PubMed  CAS  Google Scholar 

  81. Zbar B. Von Hippel-Lindau disease and sporadic renal cell carcinoma. Cancer Surv. 1995;25:219–32.

    PubMed  CAS  Google Scholar 

  82. Choyke PL, Glenn GM, Walther MM, Zbar B, Weiss GH, Alexander RB, et al. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR Am J Roentgenol. 1992;159(6):1229–34.

    Article  PubMed  CAS  Google Scholar 

  83. Lendvay TS, Marshall FF. The tuberous sclerosis complex and its highly variable manifestations. J Urol. 2003;169(5):1635–42.

    Article  PubMed  Google Scholar 

  84. Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA. Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int. 2006;70(10):1777–82.

    Article  PubMed  CAS  Google Scholar 

  85. Liu MY, Poellinger L, Walker CL. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res. 2003;63(10):2675–80.

    PubMed  CAS  Google Scholar 

  86. Gregoire JR, Torres VE, Holley KE, Farrow GM. Renal epithelial hyperplastic and neoplastic proliferation in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1987;9(1):27–38.

    PubMed  CAS  Google Scholar 

  87. Mosetti MA, Leonardou P, Motohara T, Kanematsu M, Armao D, Semelka RC. Autosomal dominant polycystic kidney disease: MR imaging evaluation using current techniques. J Magn Reson Imaging. 2003;18(2):210–5.

    Article  PubMed  Google Scholar 

  88. Gupta S, Seith A, Sud K, Kohli HS, Singh SK, Sakhuja V, et al. CT in the evaluation of complicated autosomal dominant polycystic kidney disease. Acta Radiol. 2000;41(3):280–4.

    Article  PubMed  CAS  Google Scholar 

  89. Reed B, Nobakht E, Dadgar S, Bekheirnia MR, Masoumi A, Belibi F, et al. Renal ultrasonographic evaluation in children at risk of autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2010;56(1):50–6.

    Article  PubMed  Google Scholar 

  90. Zbar B, Glenn G, Merino M, Middelton L, Peterson J, Toro J, et al. Familial renal carcinoma: clinical ­evaluation, clinical subtypes and risk of renal carcinoma development. J Urol. 2007;177(2):461–5. Discussion 5.

    Article  PubMed  Google Scholar 

  91. Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH. The process for continuous improvement of the TNM classification. Cancer. 2004;100(1):1–5.

    Article  PubMed  Google Scholar 

  92. Flocks RH, Kadesky MC. Malignant neoplasms of the kidney; an analysis of 353 patients followed five years or more. J Urol. 1958;79(2):196–201.

    PubMed  CAS  Google Scholar 

  93. Harmer M. NM classification of malignant tumors. 3rd ed. Geneva: International Union Against Cancer; 1974.

    Google Scholar 

  94. Edge SB, editor. AJCC cancer staging manual. 7th ed. Chicago: Springer; 2010.

    Google Scholar 

  95. Howard GE, Wood CG. Staging refinements in renal cell carcinoma. Curr Opin Urol. 2006;16(5): 317–20.

    Article  PubMed  Google Scholar 

  96. Ficarra V, Novara G, Galfano A, Artibani W. Neoplasm staging and organ-confined renal cell ­carcinoma: a systematic review. Eur Urol. 2004; 46(5): 559–64.

    Article  PubMed  Google Scholar 

  97. Greene FL, editor. AJCC cancer staging manual. 6th ed. Chicago: Springer; 2002.

    Google Scholar 

  98. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol. 1999;162(6):1930–3.

    Article  PubMed  CAS  Google Scholar 

  99. Ficarra V, Schips L, Guille F, Li G, De La Taille A, Prayer Galetti T, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer. 2005;104(5):968–74.

    Article  PubMed  Google Scholar 

  100. Mitchell RE, Gilbert SM, Murphy AM, Olsson CA, Benson MC, McKiernan JM. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology. 2006;67(2):260–4.

    Article  PubMed  Google Scholar 

  101. Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, Gitlitz BJ, et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol. 2001;166(1):54–8.

    Article  PubMed  CAS  Google Scholar 

  102. Cheville JC, Blute ML, Zincke H, Lohse CM, Weaver AL. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol. 2001; 166(2):453–6.

    Article  PubMed  CAS  Google Scholar 

  103. Ficarra V, Guille F, Schips L, de la Taille A, Prayer Galetti T, Tostain J, et al. Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer. 2005;104(10):2116–23.

    Article  PubMed  Google Scholar 

  104. Klatte T, Patard JJ, Goel RH, Kleid MD, Guille F, Lobel B, et al. Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol. 2007;178(1):35–40. Discussion.

    Article  PubMed  Google Scholar 

  105. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Kwon ED, et al. pT2 classification for renal cell carcinoma. Can its accuracy be improved? J Urol. 2005;173(2):380–4.

    Article  PubMed  Google Scholar 

  106. Murphy AM, Gilbert SM, Katz AE, Goluboff ET, Sawczuk IS, Olsson CA, et al. Re-evaluation of the tumour-node-metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a). BJU Int. 2005;95(1):27–30.

    Article  PubMed  Google Scholar 

  107. Lam JS, Klatte T, Patard JJ, Goel RH, Guille F, Lobel B, et al. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol. 2007;52(1):155–62.

    Article  PubMed  Google Scholar 

  108. Siemer S, Lehmann J, Loch A, Becker F, Stein U, Schneider G, et al. Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol. 2005;173(1):33–7.

    Article  PubMed  CAS  Google Scholar 

  109. Bertini R, Roscigno M, Freschi M, Strada E, Petralia G, Pasta A, et al. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases. J Urol. 2009;181(5):2027–32.

    Article  PubMed  Google Scholar 

  110. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol. 2005;174(4 Pt 1):1218–21.

    Article  PubMed  Google Scholar 

  111. Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED, et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005;104(1):53–60.

    Article  PubMed  Google Scholar 

  112. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Kwon ED, Frank I, et al. Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved? J Urol. 2005;173(3):716–9.

    Article  PubMed  Google Scholar 

  113. Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG. Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system. Cancer. 2007;109(12):2439–44.

    Article  PubMed  Google Scholar 

  114. da Costa WH, Moniz RR, da Cunha IW, Fonseca FP, Guimaraes GC, de Cassio Zequi S. Impact of renal vein invasion and fat invasion in pT3a renal cell carcinoma. BJU Int. 2012;109(4):544–8.

    Article  PubMed  Google Scholar 

  115. Ficarra V, Righetti R, D’Amico A, Rubilotta E, Novella G, Malossini G, et al. Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology. 2001;61(1):10–5.

    Article  PubMed  CAS  Google Scholar 

  116. Whitson JM, Reese AC, Meng MV. Population based analysis of survival in patients with renal cell carcinoma and venous tumor thrombus. Urol Oncol. 2011 Jul 25.

    Google Scholar 

  117. Rabbani F, Hakimian P, Reuter VE, Simmons R, Russo P. Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology. J Urol. 2004;171(3):1057–61.

    Article  PubMed  Google Scholar 

  118. Wagner B, Patard JJ, Mejean A, Bensalah K, Verhoest G, Zigeuner R, et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol. 2009;55(2):452–9.

    Article  PubMed  Google Scholar 

  119. Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol. 2004;171 (2 Pt 1):588–91.

    Article  PubMed  Google Scholar 

  120. Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol. 2004;171(2 Pt 1): 598–601.

    Article  PubMed  Google Scholar 

  121. Nesbitt JC, Soltero ER, Dinney CP, Walsh GL, Schrump DS, Swanson DA, et al. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Ann Thorac Surg. 1997;63(6): 1592–600.

    Article  PubMed  CAS  Google Scholar 

  122. Haferkamp A, Bastian PJ, Jakobi H, Pritsch M, Pfitzenmaier J, Albers P, et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. J Urol. 2007;177(5): 1703–8.

    Article  PubMed  Google Scholar 

  123. Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, et al. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol. 2003;169(3):899–903. Discussion 4.

    Article  PubMed  Google Scholar 

  124. Thompson RH, Leibovich BC, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? J Urol. 2005;173(3): 918–21.

    Article  PubMed  Google Scholar 

  125. Terrone C, Cracco C, Porpiglia F, Bollito E, Scoffone C, Poggio M, et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol. 2006;49(2):324–31.

    Article  PubMed  Google Scholar 

  126. Dimashkieh HH, Lohse CM, Blute ML, Kwon ED, Leibovich BC, Cheville JC. Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma. J Urol. 2006; 176(5):1978–82. Discussion 82–3.

    Article  PubMed  Google Scholar 

  127. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003;169(6):2076–83.

    Article  PubMed  Google Scholar 

  128. Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol. 2010;58(4):588–95.

    Article  PubMed  Google Scholar 

  129. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–40.

    PubMed  CAS  Google Scholar 

  130. Lee C, You D, Park J, Jeong IG, Song C, Hong JH, et al. Validation of the 2009 TNM classification for renal cell carcinoma: comparison with the 2002 TNM classification by concordance index. Korean J Urol. 2011;52(8):524–30.

    Article  PubMed  Google Scholar 

  131. Uzzo RG, Cherullo EE, Myles J, Novick AC. Renal cell carcinoma invading the urinary collecting system: implications for staging. J Urol. 2002;167(6): 2392–6.

    Article  PubMed  Google Scholar 

  132. Verhoest G, Avakian R, Bensalah K, Thuret R, Ficarra V, Artibani W, et al. Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol. 2009;182(3):854–9.

    Article  PubMed  Google Scholar 

  133. Patard JJ, Leray E, Cindolo L, Ficarra V, Rodriguez A, De La Taille A, et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol. 2004;172(3):858–62.

    Article  PubMed  Google Scholar 

  134. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649–57.

    PubMed  CAS  Google Scholar 

  135. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22(16):3316–22.

    Article  PubMed  Google Scholar 

  136. Ficarra V, Novara G, Galfano A, Brunelli M, Cavalleri S, Martignoni G, et al. The ‘stage, size, grade and necrosis’ score is more accurate than the University of California Los Angeles integrated staging system for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int. 2009;103(2):165–70.

    Article  PubMed  Google Scholar 

  137. Guinan P, Sobin LH, Albaga F, et al. TNM staging of renal carcinoma: workgroup no. 3. Cancer. 1997;80(5):992–3.

    Article  PubMed  CAS  Google Scholar 

  138. Green FL, Page D, Morrow M. AJCC cancer staging manual. 6th ed. New York: Springer; 2010.

    Google Scholar 

  139. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, College of Physicians and Surgeons, Columbia University and New York Presbyterian Hospital, New York, NY, USA

    Michael J. Lipsky M.D. & Christopher M. Deibert M.D.

  2. Department of Urology, Columbia University Medical Center, 161 Fort Washington Ave, 11h floor, New York, NY, 10024, USA

    James M. McKiernan M.D.

Authors
  1. Michael J. Lipsky M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher M. Deibert M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James M. McKiernan M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James M. McKiernan M.D. .

Editor information

Editors and Affiliations

  1. , Institute of Urology, Lahey Clinic, 41 Mall Road, Burlington, 01805, Massachusetts, USA

    John A Libertino

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lipsky, M.J., Deibert, C.M., McKiernan, J.M. (2013). Epidemiology, Screening, and Clinical Staging. In: Libertino, J. (eds) Renal Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7236-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-7236-0_1

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-7235-3

  • Online ISBN: 978-1-4614-7236-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation